Brief: Kilpest India Gets U.S. FDA Emergency Use Authorization Nod For COVID Test Kit
19/06/2020 11:18
June 19 (Reuters) - Kilpest India Ltd KILP.BO :
* KILPEST INDIA - FDA GRANTED EMERGENCY USE AUTHORIZATION
FOR
MULTIPLEX REAL-TIME PCR TEST
* KILPEST INDIA - TEST INTENDED FOR QUALITATIVE DETECTION OF
NUCLEIC ACID FROM SARS-COV-2
Source text for Eikon: ID:nBSEbwTyFS
Further company coverage: KILP.BO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 3B Blackbio DX
See all newsBrief: 3B Blackbio DX Gets Tax Order For Demand Of 44.6 Million Rupees
Brief: 3B Blackbio DX Gets Order Worth 13.7 Million Rupees
Brief: 3B Blackbio Dx Gets Export Order Worth $192,800
Brief: Kilpest India Says National Company Law Tribunal Approved Scheme Of Amalgamation Between 3B Blackbio Biotech India, Kilpest India
Brief: Kilpest India Final Dividend 2.5 Rupees Per Share